Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junji Matsui

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|October 11, 2013
[Preclinical biomarker research and patient stratification of molecular target agents: the anti-angiogenic inhibitor Lenvatinib mesylate (E7080)]Junji Matsui, Yasuhiro Funahashi
Anticancer Research|April 13, 2016
Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue SarcomaSatoshi Kawano, Makoto Asano, Yusuke Adachi, et al.
Journal of Forensic Sciences|October 2, 2002
Trace elemental analysis of drugs of abuse using synchrotron radiation total reflection X-ray fluorescence analysis (SR-TXRF)Seiji Muratsu, Toshio Ninomiya, Yasushi Kagoshima, et al.
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|August 12, 2008
[Anti-tumor effect of E7080, a novel angiogenesis inhibitor]Noriyuki Koyama, Naoki Magario, Yuji Yamamoto, et al.
The Journal of Biological Chemistry|February 27, 2004
Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cellsJunji Matsui, Toshiaki Wakabayashi, Makoto Asada, et al.
Scientific Reports|February 21, 2020
Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapyKenji Ichikawa, Saori Watanabe Miyano, Yukinori Minoshima, et al.
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|November 13, 2015
[Preclinical and clinical researches of lenvatinib mesylate (Lenvima capsule), a novel antitumor agent approved for thyroid cancer treatment]Akihiko Tsuruoka, Junji Matsui, Takuya Suzuki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinaseJunji Matsui, Yasuhiro Funahashi, Toshimitsu Uenaka, et al.
Journal of Synchrotron Radiation|August 23, 2006
Crystallinity estimation of thin silicon-on-insulator layers by means of diffractometry using a highly parallel X-ray microbeamShingo Takeda, Kazushi Yokoyama, Yoshiyuki Tsusaka, et al.
Diabetes|December 12, 2002
Genetic manipulations of fatty acid metabolism in beta-cells are associated with dysregulated insulin secretionKazuhiro Eto, Tokuyuki Yamashita, Junji Matsui, et al.
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|October 11, 2013
[Preclinical biomarker research and patient stratification of molecular target agents: the anti-angiogenic inhibitor Lenvatinib mesylate (E7080)]Junji Matsui, Yasuhiro Funahashi
Anticancer Research|April 13, 2016
Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue SarcomaSatoshi Kawano, Makoto Asano, Yusuke Adachi, et al.
Journal of Forensic Sciences|October 2, 2002
Trace elemental analysis of drugs of abuse using synchrotron radiation total reflection X-ray fluorescence analysis (SR-TXRF)Seiji Muratsu, Toshio Ninomiya, Yasushi Kagoshima, et al.
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|August 12, 2008
[Anti-tumor effect of E7080, a novel angiogenesis inhibitor]Noriyuki Koyama, Naoki Magario, Yuji Yamamoto, et al.
The Journal of Biological Chemistry|February 27, 2004
Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cellsJunji Matsui, Toshiaki Wakabayashi, Makoto Asada, et al.
Scientific Reports|February 21, 2020
Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapyKenji Ichikawa, Saori Watanabe Miyano, Yukinori Minoshima, et al.
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|November 13, 2015
[Preclinical and clinical researches of lenvatinib mesylate (Lenvima capsule), a novel antitumor agent approved for thyroid cancer treatment]Akihiko Tsuruoka, Junji Matsui, Takuya Suzuki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinaseJunji Matsui, Yasuhiro Funahashi, Toshimitsu Uenaka, et al.
Journal of Synchrotron Radiation|August 23, 2006
Crystallinity estimation of thin silicon-on-insulator layers by means of diffractometry using a highly parallel X-ray microbeamShingo Takeda, Kazushi Yokoyama, Yoshiyuki Tsusaka, et al.
Diabetes|December 12, 2002
Genetic manipulations of fatty acid metabolism in beta-cells are associated with dysregulated insulin secretionKazuhiro Eto, Tokuyuki Yamashita, Junji Matsui, et al.
Pageof 7